NMLS.D Stock Overview
Through its subsidiaries, operates as a biotechnology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Restart Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.089 |
| 52 Week Low | CA$0.01 |
| Beta | 0.63 |
| 11 Month Change | 6.38% |
| 3 Month Change | -39.10% |
| 1 Year Change | -72.83% |
| 33 Year Change | -91.44% |
| 5 Year Change | -97.16% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| NMLS.D | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 57.0% | 2.5% | 2.2% |
| 1Y | -72.8% | 16.1% | 31.6% |
Return vs Industry: NMLS.D underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: NMLS.D underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| NMLS.D volatility | |
|---|---|
| NMLS.D Average Weekly Movement | 76.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NMLS.D's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NMLS.D's weekly volatility has increased from 48% to 76% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Steve Loutskou | www.restartlife.co |
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024.
Restart Life Sciences Corp. Fundamentals Summary
| NMLS.D fundamental statistics | |
|---|---|
| Market cap | US$848.90k |
| Earnings (TTM) | -US$449.71k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.9x
P/E RatioIs NMLS.D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NMLS.D income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$628.58k |
| Earnings | -CA$628.58k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -5.7% |
How did NMLS.D perform over the long term?
See historical performance and comparison